MX2014010664A - Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. - Google Patents

Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.

Info

Publication number
MX2014010664A
MX2014010664A MX2014010664A MX2014010664A MX2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A
Authority
MX
Mexico
Prior art keywords
methods
chop2
channelrhodopsin
mutations
identification
Prior art date
Application number
MX2014010664A
Other languages
English (en)
Other versions
MX360085B (es
Inventor
Zhuo-Hua Pan
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Publication of MX2014010664A publication Critical patent/MX2014010664A/es
Publication of MX360085B publication Critical patent/MX360085B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona composiciones y kits que incluyen al menos un ácido nucleico o molécula de polipéptido que codifica una proteína ChR2 mutante. Los métodos de la invención incluyen administrar una composición que comprende un ChR2 mutante a un sujeto para conservar, mejorar, o restaurar la fototransducción. Preferiblemente, las composiciones y métodos de la invención se proporcionan a un sujeto que tiene visión disminuida, de este modo restaurar la visión a los niveles normales.
MX2014010664A 2012-03-05 2013-03-05 Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. MX360085B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (2)

Publication Number Publication Date
MX2014010664A true MX2014010664A (es) 2015-03-06
MX360085B MX360085B (es) 2018-10-10

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010664A MX360085B (es) 2012-03-05 2013-03-05 Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.

Country Status (17)

Country Link
US (2) US10947281B2 (es)
EP (1) EP2822964B1 (es)
JP (3) JP6395611B2 (es)
KR (1) KR102137717B1 (es)
CN (2) CN104334575A (es)
AU (4) AU2013230112A1 (es)
CA (1) CA2866405A1 (es)
DK (1) DK2822964T3 (es)
EA (1) EA201491643A1 (es)
ES (1) ES2703324T3 (es)
HK (1) HK1205744A1 (es)
HU (1) HUE040487T2 (es)
MX (1) MX360085B (es)
NZ (1) NZ629843A (es)
PL (1) PL2822964T3 (es)
PT (1) PT2822964T (es)
WO (1) WO2013134295A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
EP2822964B1 (en) 2012-03-05 2018-08-22 Wayne State University Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EP2968476B1 (en) 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
US10234761B2 (en) 2013-07-08 2019-03-19 Basf Se Oxime ester photoinitiators
WO2015138616A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
US20170319669A1 (en) 2016-05-03 2017-11-09 Wayne State University Method of enhancing viral-mediated gene delivery
KR20190020702A (ko) * 2016-06-03 2019-03-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 채널로돕신의 돌연변이 광-유도성 이온 채널
EP3504227A1 (en) * 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
US11180537B2 (en) * 2016-11-06 2021-11-23 Nancoscope Technologies LLC Optogenetic modulation by Multi-Characteristic Opsins for vision restoration and other applications
CN111032068A (zh) * 2017-04-12 2020-04-17 马克斯·普朗克科学促进学会 新的光遗传学工具
BR112020011160A2 (pt) * 2017-12-04 2020-11-17 Laboratorios Salvat, S.A. composição tópica oftálmica para o tratamento de doenças do segmento posterior do olho
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
WO1998048027A2 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
NZ511037A (en) 1998-09-17 2005-02-25 Univ Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7427138B2 (en) 2003-11-05 2008-09-23 Neurovision, Inc. Method and apparatus for improving visual perception
EP2465925A1 (en) 2005-07-22 2012-06-20 The Board Of Trustees Of The Leland Light-activated cation channel and uses thereof
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
SG188409A1 (en) * 2010-09-08 2013-04-30 Max Planck Gesellschaft Mutant channelrhodopsin 2
EP2822964B1 (en) 2012-03-05 2018-08-22 Wayne State University Identification of channelrhodopsin-2 (chop2) mutations and methods of use
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
CA2866405A1 (en) 2013-09-12
JP6395611B2 (ja) 2018-09-26
AU2021245195B2 (en) 2023-09-28
HK1205744A1 (en) 2015-12-24
AU2017239601B2 (en) 2019-05-16
CN104334575A (zh) 2015-02-04
AU2019216638A1 (en) 2019-09-05
CN111378020A (zh) 2020-07-07
AU2013230112A1 (en) 2014-09-25
KR20140132401A (ko) 2014-11-17
JP2018134098A (ja) 2018-08-30
US20150044181A1 (en) 2015-02-12
JP2019193656A (ja) 2019-11-07
MX360085B (es) 2018-10-10
AU2019216638B2 (en) 2021-07-08
NZ629843A (en) 2017-03-31
EP2822964B1 (en) 2018-08-22
KR102137717B1 (ko) 2020-07-27
US20220033449A1 (en) 2022-02-03
PT2822964T (pt) 2018-11-29
DK2822964T3 (en) 2018-12-10
US10947281B2 (en) 2021-03-16
AU2021245195A1 (en) 2021-11-04
EA201491643A1 (ru) 2015-02-27
EP2822964A1 (en) 2015-01-14
AU2017239601A1 (en) 2017-10-26
JP2015510759A (ja) 2015-04-13
PL2822964T3 (pl) 2019-05-31
NZ727041A (en) 2022-01-28
ES2703324T3 (es) 2019-03-08
HUE040487T2 (hu) 2019-03-28
WO2013134295A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
WO2017191274A3 (en) Rna encoding a therapeutic protein
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2009002816A (es) Proteinas de fusion de albumina.
MX2017009153A (es) Proteinas de fusion de citoquinas.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
PH12014501991B1 (en) Phenicol antibacterials
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
PH12015500771A1 (en) Novel fc gamma receptor iib variants
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
BR112013005711A2 (pt) método para tratar um tumor, mutante, molécula de ácido nucleico isolada, construção de expressão, composição, e, método para administrar uma terapia
MX2019002321A (es) Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.
GB201019467D0 (en) Therapeutic agent
BR112018016920A2 (pt) indutor da imunidade, célula apresentadora de antígeno isolada, célula t isolada, polipeptídeo, agente para tratar ou prevenir o câncer e método de tratamento ou prevenção do câncer
GB201204283D0 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration